Novartis pushes back regulatory filing of Rett syndrome gene therapy

Novartis completed its acquisition of AveXis in May 2018 for $8.7bn and successfully brought AveXis’ most advanced asset, Zolgensma past FDA approval on May 2019 for spinal muscular atrophy.